Active Funding Opportunities:

NIH Highlighted Topics

When beginning your next investigator-initiated application, consider the following NIH highlighted topic. The area of science described below is of interest to the listed NIH Institutes, Centers, and Offices (ICOs). This is not a notice of funding opportunity (NOFO).
Apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants.gov. Learn how to interpret and use Highlighted Topics.

Technology Development for Genomics
Posted Date: August 29, 2025
Expiration Date: August 29, 2026
Lead ICO: NHGRI
Participating ICOs: NHGRI, NIAID, NIDA, NLM, ORWH

NIH Parent Funding Announcements (partial list)

PA-25-301: R01 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
Open Date: January 05, 2025
Expiration Date: January 08, 2028

PA-25-304: R21 NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
Open Date: January 16, 2025
Expiration Date: January 08, 2028

PA-24-247: R41/42 PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
Open Date: August 08, 2024
Expiration Date: September 06, 2025

PA-24-245: R43/44 PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
Open Date: August 08, 2024
Expiration Date: September 06, 2025

Request for Applications (RFA)

Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)
RFA-HG-25-009:
Next Application Due Date: February 28, 2025
Expiration Date: February 27, 2027

Program Announcement with Special Review (PAR)

Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R01 Clinical Trial Not Allowed)
PAR-25-255
Application Due Dates: Standard Dates
Expiration Date: November 6, 2026

Developing Novel Theory and Methods for Understanding the Genetic Architecture of Complex Human Traits (R21 Clinical Trial Not Allowed)
PAR-25-256
Application Due Dates: Standard Dates
Expiration Date: January 8, 2027

Funding for New and Early-Stage Investigators

PAR-24-075: Stephen I. Katz Early Stage Investigator Research Project Grant (R01, Clinical Trial Not Allowed)
*First due date is January 26, 2024; Expiration date is December 29, 2026

(click here for additional early-stage investigator resources)

For additional information and more funding opportunities, please visit NHGRI Research Funding and NIH Parent Funding Announcements

Inactive Funding Opportunities:

NHGRI Technology Development Coordinating Center

RFA-HG-24-013: NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)

Notice of Special Interest (NOSI)

NOT-HG-24-012: Advancing Genomic Technology Development for Research and Clinical Application
NOT-HG-21-018: Advancing Genomic Technology Development for Research and Clinical Application
NOT-HG-24-036: Advancing Genomic Technology Development for Research and Clinical Application

Notice of Funding Opportunity (NOFO)

RFA-HG-24-013: NHGRI Technology Dvelopment Coordinating Center (U24)

RFAs

  • RFA-HG-21-006: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial not Allowed)
  • RFA-HG-21-007: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial not Allowed)
  • RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)
  • RFA-HG-21-001: Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial not allowed)
  • RFA-HG-21-002: Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed)
  • RFA-HG-20-014: Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)
  • RFA-HG-20-015: Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed)
  • RFA-HG-20-016: Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)
  • RFA-HG-20-019: NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
  • RFA-HG-18-001: Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)
  • RFA-HG-18-002: Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)
  • RFA-HG-18-003: Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)

PARs

  • PAR-23-098: Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
  • PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed)
  • PAR-18-777: Novel Genomic Technology Development (R01 Clinical Trial Not Allowed)
  • PAR-18-778: Novel Genomic Technology Development (R21 Clinical Trial Not Allowed)
  • PAR-18-779: Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)

Updated 09/04/2025